|
| 36222845 | Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. | Cancer Discov | 2023 |
| 37587783 | Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self-administered questionnaire to an initial screening platform. | Eur J Haematol | 2023 |
| 37576365 | Anti-Spike Antibody Responses in Allogeneic Stem Cell Transplant Recipients to Two Doses of COVID-19 mRNA Vaccination: A Retrospective, Single-Center Analysis. | J Adv Pract Oncol | 2023 |
| 37601838 | Serum D-2-hydroxyglutarate and the ratio of D-2HG/L-2HG predict <i>IDH</i> mutation in acute myeloid leukemia. | EJHaem | 2023 |
| 37326395 | SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation. | Acta Med Acad | 2023 |
| 37078412 | Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. | Cancer | 2023 |
| 36842566 | Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience. | Transpl Immunol | 2023 |
| 36459761 | Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei. | Leuk Res | 2023 |
| 36566538 | Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort. | Leuk Res | 2023 |
| 36315007 | Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. | Blood Adv | 2023 |
| 34482403 | Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. | Blood | 2022 |
| 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 |
| 36102633 | Genomic profile of TdT<sup>positive</sup> MYC/BCL2 rearranged high-grade B-cell lymphoma supporting its diagnosis as mature aggressive lymphoma. | Cytometry B Clin Cytom | 2022 |
| 35133215 | The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. | Leuk Lymphoma | 2022 |
| 32918786 | Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. | Cytometry B Clin Cytom | 2021 |
| 33781572 | Corrigendum to "The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement" [Leukemia Res. 100 (2021) 106480]. | Leuk Res | 2021 |
| 33772143 | Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. | Leukemia | 2021 |
| 33933715 | MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia. | Leuk Res | 2021 |
| 33285315 | The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement. | Leuk Res | 2021 |
| 32145771 | Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. | Lancet Haematol | 2020 |
| 31880950 | Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. | J Clin Oncol | 2020 |
| 33106665 | Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. | Nat Med | 2020 |
| 30510081 | Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenib. | Blood | 2019 |
| 35100680 | Next-Generation Sequencing Directs Therapy and Delineates a Clonal Relationship in Mast Cell Sarcoma and Acute Myeloid Leukemia. | JCO Precis Oncol | 2019 |
| 31366621 | Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. | Blood | 2019 |
| 30967620 | Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. | Leukemia | 2019 |
| 30651561 | Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. | Nat Commun | 2019 |
| 29722657 | Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy. | Int J Radiat Oncol Biol Phys | 2018 |
| 29860938 | Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. | N Engl J Med | 2018 |
| 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 |
| 30333625 | LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. | Nature | 2018 |
| 27941793 | Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. | Nat Med | 2017 |
| 28411378 | Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. | Cancer | 2017 |
| 28459703 | Novel Cytogenetic Findings in a Case of Mixed Phenotype Acute Leukemia within the Context of a Complex Karyotype. | J Assoc Genet Technol | 2017 |
| 28355571 | Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. | Cell Rep | 2017 |
| 28377936 | Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation. | ACG Case Rep J | 2017 |
| 28122742 | Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. | Blood | 2017 |
| 28784769 | Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. | Proc Natl Acad Sci U S A | 2017 |
| 28588020 | Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia. | Blood | 2017 |
| 28862883 | Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. | J Clin Oncol | 2017 |
| 26195003 | The importance of plasma D-2HG measurement in screening for IDH mutations in acute myeloid leukaemia. | Br J Haematol | 2016 |
| 28430957 | CD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients. | Am J Clin Pathol | 2016 |
| 26426250 | Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer. | JAMA Oncol | 2016 |
| 26968357 | Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. | Lancet Oncol | 2016 |
| 25915125 | The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. | Nat Cell Biol | 2015 |
| 26110425 | Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. | PLoS One | 2015 |
| 24579926 | Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. | Br J Haematol | 2014 |
| 23656643 | Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. | N Engl J Med | 2013 |
| 26030620 | A Chronic Myelogenous Leukemia (CML) Case with a Cryptic Insertion of the ABL1 Gene of Chromosome 9 into 22 Resulting in a Fusion Signal on the Derivative 22: 46,XY.ish ins(22;9)(q11.2;q34q34)BCR+,ABL1. | J Assoc Genet Technol | 2013 |
| 22585697 | Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. | J Clin Oncol | 2012 |